IRWD News and Press, Ironwood Pharmaceuticals Inc. From 01/31/24

2024-01-31 13:59:32 ET Summary Ironwood Pharmaceuticals has established itself as a leader in the gastrointestinal healthcare space with its innovative products and pipeline development. The demand for LINZESS, a therapy for irritable bowel syndrome, is increasing, contributing to...

– Newly published data highlights additional efficacy endpoints from trial – – Linaclotide is the first and only FDA-approved prescription therapy for children and adolescents aged 6-17 years with functional constipation – Ironwood Pharmaceuticals...

2024-01-08 07:53:55 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2023 Earnings Call Transcript Ironwood Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Ironwood Pharmaceuticals: The Right Play Now Jefferies...

– Expects high-single digit percentage LINZESS® EUTRx prescription demand growth in 2024 – – Expects 2024 adjusted EBITDA of greater than $150 million – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare compan...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 11:15 a.m. Pacific Time / 2:15 p.m. Eastern Time at The Westin St. Fran...

2024-01-02 12:13:42 ET More on Markets S&P, Dow, Nasdaq dip, yields jump to kick off 2024 Gap between all-time highs for the S&P 500 is the sixth longest in history 2024 Analyst Outlook: Julian Lin On What's Next For AI, Large Cap Tech And Cannabis Investing ...

2023-12-15 01:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, today announced the successful completion of the squeeze-out merger under Swiss law (the “Squeeze-Out Merger”) pursuant to which VectivBio Holding AG (“VectivBio”...

Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and it...

2023-11-27 10:34:03 ET More on Tharimmune, Inc. Financial information for Tharimmune, Inc. For further details see: Tharimmune stock rockets 46% on positive Phase 1 data for PBC drug